- Source: Pimodivir
Pimodivir (VX-787, JNJ-63623872) is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials. However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care.
See also
Baloxavir marboxil
Favipiravir
Galidesivir
Nitazoxanide
Oseltamivir
Peramivir
Remdesivir
Ribavirin
Triazavirin
Umifenovir
Zanamivir